Back to Journals » Therapeutics and Clinical Risk Management » Volume 3 » Issue 6

Long-term safety and effectiveness of sildenafil citrate in men with erectile dysfunction

Authors James G McMurray, Robert A Feldman, Stephen M Auerbach, Herb DeRiesthal, Neal Wilson et al

Published 15 January 2008 Volume 2007:3(6) Pages 975—981

James G McMurray1, Robert A Feldman2, Stephen M Auerbach3, Herb DeRiesthal4 Neal Wilson5, On behalf of the Multicenter Study Group6

1Medical Affiliated Research Center, Huntsville, AL, USA; 2Connecticut Clinical Research Center, Waterbury, CT, USA; 3California Professional Research, Newport Beach, CA, USA; 4Pfizer Inc, New York, NY, USA; 5Formerly Pfizer Global Research and Development, Sandwich, UK, currently PPD Inc, Cambridge, UK; 6Members of the multicenter study group are listed in the appendix.

Abstract: Because sildenafil citrate is a treatment, not a cure, for erectile dysfunction (ED), many men may choose to use it for an extended period. Men with ED who had previously completed 1 of 4 double-blind trials with short-term open-label extension (combined duration, 0.9–1.2 years) were eligible for this 4-year, open-label, extension study, which assessed the safety and effectiveness of flexible doses (25, 50, and 100 mg sildenafil) used as needed. Adverse events that were serious or led to dosing changes or discontinuation (temporary or permanent) were recorded. Many of the 979 participants (mean age, 58 [range, 27–82] years; mean ED duration, 4.5 years) had concomitant hypertension (28%), diabetes (22%), or hyperlipidemia (14%). Overall, 37 (3.8%) had treatment-related adverse events (none serious) requiring dosage change or discontinuation and 62 (6.3%) discontinued because of insufficient response. At each yearly assessment, more than 94% of participants responded affirmatively to the questions: “Are you satisfied with the effect of treatment on your erections?” and “If yes, has treatment improved your ability to engage in sexual activity?” These results argue against the loss of tolerability or the development of tachyphylaxis over a prolonged period of as needed, flexible-dose sildenafil treatment of men with ED.
Keywords: sildenafil citrate, erectile dysfunction, tolerability, effectiveness

Download Article [PDF] 

Readers of this article also read:

Impact of aerobic exercise on sleep and motor skills in children with autism spectrum disorders – a pilot study

Brand S, Jossen S, Holsboer-Trachsler E, Pühse U, Gerber M

Neuropsychiatric Disease and Treatment 2015, 11:1911-1920

Published Date: 5 August 2015

Acceleration training for managing nonalcoholic fatty liver disease: a pilot study

Oh S, Shida T, Sawai A, Maruyama T, Eguchi K, Isobe T, Okamoto Y, Someya N, Tanaka K, Arai E, Tozawa A, Shoda J

Therapeutics and Clinical Risk Management 2014, 10:925-936

Published Date: 7 November 2014

Satisfaction of hospitalized psychiatry patients: why should clinicians care?

Zendjidjian XY, Baumstarck K, Auquier P, Loundou A, Lançon C, Boyer L

Patient Preference and Adherence 2014, 8:575-583

Published Date: 25 April 2014

Examining the clinical trial feasibility process and its implications for a trial site

Burgess LJ, Sulzer NU

Open Access Journal of Clinical Trials 2011, 3:51-54

Published Date: 9 September 2011

Benefits and drawbacks of electronic health record systems

Menachemi N, Collum T

Risk Management and Healthcare Policy 2011, 4:47-55

Published Date: 11 May 2011

α-L-iduronidase therapy for mucopolysaccharidosis type I

Jakub Tolar, Paul J Orchard

Biologics: Targets and Therapy 2008, 2:743-751

Published Date: 5 December 2008

A pilot feasibility study of daily rTMS to modify corticospinal excitability during lower limb immobilization

Raffaella Ricci, Dave Ramsey, Kevin Johnson, Jeffrey J Borckardt, Matthew Vallejo, et al

Therapeutics and Clinical Risk Management 2008, 4:1127-1134

Published Date: 10 October 2008